Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 1/2 6Phase 3 4Phase 2/3 2Phase 1 2

Status

Unknown 4Completed 4Recruiting 2Not yet recruiting 2Active not recruiting 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioblastoma 1Advanced Glioblastoma 1

Interventions

Cisplatin 10Gemcitabine 7Fluorouracil 7Carboplatin 7Capecitabine 7venetoclax 5Oxaliplatin 5Cyclophosphamide 4sintilimab 3Radiotherapy 3Neoadjuvant Therapy 3Dexamethasone 3Bevacizumab 3Azacitidine 3130-nm albumin-bound paclitaxel 3trametinib 2regorafenib 2pembrolizumab 2nimotuzumab 2fludarabine 2disitamab vedotin 2daratumumab 2dabrafenib 2camrelizumab 2blinatumomab 2apatinib 2Trastuzumab 2Temozolomide 2Radiotherapy, Intensity-Modulated 2Radiation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Not yet recruiting × Temozolomide × Clear all
NCT07605364 2026-05-26

Testing the Addition of an Anti-Cancer Drug, Mycophenolate Mofetil, to the Usual Treatment (Radiation Therapy and Temozolomide) for Advanced Brain Cancer

Alliance for Clinical Trials in Oncology

Phase 2/3 Not yet recruiting
422 enrolled
CNS

Advanced Glioblastoma

NCT07349693 2026-01-20

Cerebraca-02/3

Everfront Biotech Co., Ltd.

Phase 2/3 Not yet recruiting
175 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡